A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy of ciclesonide metered-dose inhaler at a daily dose of 160 μg administered for twelve weeks either in a once-daily regimen in the morning (160 micrograms qd AM) or in a twice daily regimen (80 micrograms bid) in adults and adolescents with mild to moderate persistent asthma treated previously with inhaled corticosteroids

Trial Profile

A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy of ciclesonide metered-dose inhaler at a daily dose of 160 μg administered for twelve weeks either in a once-daily regimen in the morning (160 micrograms qd AM) or in a twice daily regimen (80 micrograms bid) in adults and adolescents with mild to moderate persistent asthma treated previously with inhaled corticosteroids

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Jul 2009

At a glance

  • Drugs Ciclesonide (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 07 Jul 2009 Actual patient number changed from 446 to 456 as reported by ClinicalTrials.gov.
    • 19 May 2009 Results reported at the 105th International Conference of the American Thoracic Society.
    • 22 Sep 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top